ABL-specific tyrosine kinase inhibitors (TKIs) induce minimal apoptosis in CML progenitor cells, yet exert potent antiproliferative effects, through as yet poorly understood mechanisms. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.